A carregar...
Critical appraisal of bevacizumab in the treatment of ovarian cancer
Bevacizumab is the first molecular-targeted agent to be used for the treatment of ovarian cancer. Bevacizumab is a humanized monoclonal antibody targeting vascular endothelial growth factor. Two randomized Phase III trials evaluated the combination of bevacizumab plus standard cytotoxic chemotherapy...
Na minha lista:
| Publicado no: | Drug Des Devel Ther |
|---|---|
| Main Authors: | , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Dove Medical Press
2015
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4423500/ https://ncbi.nlm.nih.gov/pubmed/25960638 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/DDDT.S83275 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|